Cellectar Targets EU Approval for Iopofosine as Cash Runs Thin
Event summary
- Cellectar plans to submit a Conditional Marketing Authorization for iopofosine I-131 in Europe by Q3 2026, targeting Waldenström Macroglobulinemia.
- Phase 1b study of CLR 125 in Triple Negative Breast Cancer initiated; early data expected mid-2026.
- Cash position dropped to $13.2M at year-end 2025 from $23.3M, sufficient for operations into Q3 2026.
- Net loss narrowed to $21.8M in 2025 from $44.6M in 2024.
The big picture
Cellectar's push for EU approval of iopofosine reflects a strategic pivot toward regulatory milestones as it navigates a tight financial runway. The company's focus on radiotherapeutic platforms aligns with broader industry trends favoring targeted cancer treatments, but execution risks loom large given its cash constraints and reliance on clinical trial success.
What we're watching
- Regulatory Momentum
- Whether Cellectar can secure Conditional Marketing Authorization in Europe by mid-2026, accelerating iopofosine's commercialization.
- Clinical Pipeline
- The pace at which CLR 125 advances through Phase 1b and whether early data supports progression to Phase 2.
- Financial Sustainability
- How Cellectar extends its cash runway beyond Q3 2026 amid high R&D expenses.
Our editorial coverage:
Related topics